Childhood Absence Epilepsy Treatment Market
- 2026 年市場規模
- USD 300 Mn
- 2033 年預估規模
- USD 520 Mn
- 年複合成長率 CAGR
- 8.2%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Childhood Absence Epilepsy Treatment Market, By Drug (Ethosuximide, Valproate, Lamotrigine, and Phase 2 Drugs (Cannabidiol Oral Solution and CX-8998)), By Disease Type (Typical Absence Seizures and Atypical Absence Seizures), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
Childhood absence epilepsy diagnosis revolves around identifying symptoms and categorizing the epilepsy type based on those symptoms. Diagnostic methods and techniques for childhood absence epilepsy include electroencephalogram (EEG)/video telemetry, magnetic resonance imaging (MRI scans), and blood tests. In electroencephalogram (EEG)/video telemetry, electrical signals from brain are recorded in a computer by asking the patient to hyperventilate for 3 to 5 minutes, which triggers an absence seizure. The EEG then shows spikes and wave discharges at 3 Hz (cycles per second) that are generalized in nature (similar on both sides of the brain). Structural causes behind epilepsy can be understood with the help of MRI scans (as some patients suffering from epilepsy due to brain damage can be found by a MRI scan). Blood tests may be required to diagnose any medical conditions, which may be the reason behind epilepsy.
Market Dynamics
Key players in the market are focused on the development of new drugs for the treatment of childhood absence epilepsy. Factors such as increasing prevalence of the disease, increasing accessibility of medications, and presence of drugs in pipeline for childhood absence epilepsy treatment (Insys therapeutics and Cavion, Inc.) are expected to boost the global childhood absence epilepsy treatment market growth. Product launches by generic manufacturers in the U.S. as well as globally is expected to support growth of the market. For instance, Dr. Reddy’s Laboratories launched generic lamotrigine orally disintegrating tablets in the U.S. in 2016. Moreover, a number of manufacturers such as Insys Therapeutics (Cannabidiol) and Cavion, Inc. (CX-8998) have drugs in phase II stage in clinical trials and these therapies are expected to be launched over the forecast period.
Key features of the study
• This report provides in-depth analysis of childhood absence epilepsy treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global childhood absence epilepsy treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
• Key companies covered as a part of this study include Cavion, Inc., Pfizer, Inc., GlaxoSmithKline Plc, Insys Therapeutics, Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
• The global childhood absence epilepsy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the childhood absence epilepsy treatment market
Market Segmentation
• By Drug (Revenue, USD Mn, 2021-2033)
o Ethosuximide
o Valproate
o Lamotrigine
o Phase 2 Drugs
Cannabidiol Oral Solution
CX-8998
• By Disease Type (Revenue, USD Mn, 2021-2033)
o Typical Absence Seizures
o Atypical Absence Seizures
• By Region (Revenue, USD Mn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Cavion, Inc.
o Pfizer, Inc.
o GlaxoSmithKline Plc
o Insys Therapeutics, Inc.
o AbbVie, Inc.
o Teva Pharmaceutical Industries Ltd.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug
Market Snapshot, By Disease Type
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Childhood Absence Epilepsy Treatment Market, By Drug, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Ethosuximide
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Valproate
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Lamotrigine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Phase 2 Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
Segment Trends
o Cannabidiol Oral Solution
o CX-8998
5. Global Childhood Absence Epilepsy Treatment Market, By Disease Type, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Typical Absence Seizures
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Atypical Absence Seizures
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
6. Global Childhood Absence Epilepsy Treatment Market, By Region, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Million)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Cavion, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
GlaxoSmithKline Plc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Insys Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
AbbVie, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Teva Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們